ReviewFrontiers in molecular biosciences2026
Mesenchymal stem cells-derived extracellular vesicles as a novel drug delivery carrier: engineering strategies and clinical safety estimation.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-Mediated Drug Delivery: From Carriers to Therapeutics.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have biocompatibility and low immunogenicity. They can effectively mediate intercellular communication by transmitting various information molecules, including polypeptides, lipids, and nucleic acids, thereby demonstrating unique potential in the field of drug delivery. Given their crucial roles in immune regulation and regenerative medicine, an increasing number of studies are focusing on developing MSC-EVs as drug carriers. This paper presents a systematic review of the future development directions of MSC-EVs as drug carriers, with a particular emphasis on their origins and engineering modification or pretreatment strategies. By employing engineering techniques to modify MSC-EVs, it is possible to precisely regulate key properties such as drug-loading capacity and targeting ability, thereby providing a novel approach for efficient drug delivery. Meanwhile, this paper delves into the safety evaluation of MSC-EVs in clinical applications across different diseases, comprehensively assessing their safety and efficacy as drug carriers based on clinical studies in the fields of lungs, skin, nervous system, eyes, and gastrointestinal tract, among others. Furthermore, we provide an outlook on the potential value and challenges associated with the clinical application of MSC-EVs as drug carriers in various diseases in the future, aiming to offer theoretical support and research directions for promoting MSC-EVs as safe and effective drug carriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.